Request Inspection Copy

If you are an Academic or Teacher and wish to consider this book as a prescribed textbook for your course, you may be eligible for a complimentary inspection copy. Please complete this form, including information about your position, campus and course, before adding to cart.

* Required Fields

To complete your Inspection Copy Request you will need to click the Checkout button in the right margin and complete the checkout formalities. You can include Inspection Copies and purchased items in the same shopping cart, see our Inspection Copy terms for further information.

Any Questions? Please email our text Support Team on text@footprint.com.au

Submit

Email this to a friend

* ALL required Fields

Order Inspection Copy

An inspection copy has been added to your shopping cart

Sage Handbook of Healthcare

by Decision Resources Inc SAGE Publications Ltd
Pub Date:
05/2008
ISBN:
9781847870483
Format:
Hbk 752 pages
Price:
AU$275.00 NZ$280.00
Product Status: Available in Approx 14 days
add to your cart
Available as eBook
AU$220.00 | NZ$245.83

Other Available Formats:

With escalating healthcare costs, changes to the regulatory control on pharmaceutical industries and the inevitable adjustments made in policies and investment in healthcare there is enormous interest in the commercial as well as the scientific aspects of today's healthcare industry.
The SAGE Handbook of Healthcare provides an authoritative analysis of the current (and anticipated) developments in the global healthcare industries. Providing a unique perspective that interfaces between the science and business aspects, it combines information on the latest scientific developments with applied, commercial business data from the global marketplace.
The Handbook focuses on the aspects of paramount importance in the healthcare sector:
Pharmacoeconomics
Pharmacogenomics
Therapeutics
Diagnostics
Areas covered include:
The role of nanotechnology, genomics and cell therapy in medicine
Diagnostics; Biomarkers and technological advances
Case studies in oncology and cardiovascular and CNS therapeutics

PART ONE: PHARMACOECONOMICS Medicare Part D An Outlook Changes in US Oncology Drug Reimbursement Medicare Sets The Pace Prospective Payment Systems Opportunities and Threats for the Pharmaceutical Industry Off-label Prescribing Overcoming the Reimbursement Barrier Pricing and Reimbursement Issues in Neurology Authorized Generics Look Before You Leap Pharmaceutical Pricing and Reimbursement in Canada Contrasting European and US Patent Laws Issues for the Pharmaceutical Industry The Changing Face of European Drug Registration The Impact of Reference Pricing in Europe Pharmaceutical Pricing, Reimbursement, and Prescribing in the United Kingdom Pharmaceutical Pricing, Reimbursement, and Prescribing in Italy Pharmaceutical Pricing, Reimbursement, and Prescribing in Spain The Impact of German Reference Pricing on Statins Opportunities and Challenges in the Japanese Market for Cancer Therapies Cancer Therapies Face Increasing Reimbursement Pressures in Europe and Japan The Pharmaceutical Pricing and Reimbursement Environment in China Will Point of Care Come of Age by 2010? PART TWO: PHARMACOGENOMICS Has Genomics Failed to Deliver? The Role of Pharmacogenomics in Personalized Medicine Cell Therapy A Decade of Opportunity Nanotechnology in Medicine Its Time Has Come Clinical Proteomics An Engine for In Vitro Diagnostics Growth? PART THREE: THERAPEUTICS Oncology Novel Strategies in Oncology Clinical Trials The Use of Biological and Imaging Biomarkers Antitumor Biologics Strategies for Success in an Expanding Market Outlook for Cancer Vaccine Development Advances Imminent in Antiangiogenesis Therapeutics Discoveries and Challenges in Early-stage Apoptosis Drug Development Chronic Lymphocytic Leukemia Monoclonal Antibodies Will Drive Steady Growth CNS Opportunities in the Pharmacotherapy of Addiction Immunology Prevention of Organ Transplant Rejection Current Therapies and Novel Strategies Cardiovascular Cardiovascular Drugs and Devices Market Some Successes and Setbacks in Recent Years Renin Inhibitors A Novel Approach to Hypertension Future of VLA-4 Antagonist Drugs and Implications for the Regulatory Process Impact of Inhaled Insulin on the Insulin Market Impact of the PROactive Study on the Treatment of Type 2 Diabetes PART FOUR: DIAGNOSTICS Integrating Diagnostics and Therapeutics for Targeted Therapies Part 1: Optimizing the Comarketing Plan Integrating Diagnostics and Therapeutics for Targeted Therapies Part 2: The Importance of Calculating the Return on Investment Emerging Diagnostic Markers in Alzheimer's Disease How are Translational Medicine Biomarkers Impacting Industry? Unlocking the Potential of Biomarkers in Targeted Oncology From Bioterrorism to Predictive Medicine: New Applications of Salivary Diagnostics